Fig. 2.
Fig. 2. Effect of 2ME2 on BMSCs and IL-6 secretion. / (A) Patient MM-derived BMSCs (patients A-C) were treated with 2ME2 (3-9 μM) for 72 hours, and viability was assessed by MTT assay. Results are the mean ± SD from triplicate samples; P = .002. (B) 2ME2 induced proteolytic cleavage of PARP in patient MM-BMSCs cells. BMSCs from 2MM patients were treated with 2ME2 (3 μM) for 72 hours and harvested; total protein lysates were subjected to SDS-PAGE analysis. Immunoblot analysis of the lysates was performed with anti-PARP antibody. FL indicates full length; CF, cleaved fragment. (C) Effect of 2ME2 on MM cell adhesion–induced IL-6 secretion in BMSCs. IL-6 levels were measured using IL-6–specific ELISA in supernatants of 24-hour cultures of BMSCs, MM.1S cells, and BMSCs + MM.1S cells, in the presence or absence of 2ME2 (3 μM).

Effect of 2ME2 on BMSCs and IL-6 secretion.

(A) Patient MM-derived BMSCs (patients A-C) were treated with 2ME2 (3-9 μM) for 72 hours, and viability was assessed by MTT assay. Results are the mean ± SD from triplicate samples; P = .002. (B) 2ME2 induced proteolytic cleavage of PARP in patient MM-BMSCs cells. BMSCs from 2MM patients were treated with 2ME2 (3 μM) for 72 hours and harvested; total protein lysates were subjected to SDS-PAGE analysis. Immunoblot analysis of the lysates was performed with anti-PARP antibody. FL indicates full length; CF, cleaved fragment. (C) Effect of 2ME2 on MM cell adhesion–induced IL-6 secretion in BMSCs. IL-6 levels were measured using IL-6–specific ELISA in supernatants of 24-hour cultures of BMSCs, MM.1S cells, and BMSCs + MM.1S cells, in the presence or absence of 2ME2 (3 μM).

Close Modal

or Create an Account

Close Modal
Close Modal